(Q31913332)

5 July 2017

title

Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease (English)

1 reference

5 July 2017

0 references

Schmidt N

1

1 reference

5 July 2017

Ferger B

series ordinal

2

1 reference

5 July 2017

publication date

1 April 2001

1 reference

5 July 2017

1 reference

5 July 2017

volume

40

1 reference

5 July 2017

issue

1

1 reference

5 July 2017

page(s)

47-54

1 reference

Extract of kava (Piper methysticum) and its methysticin constituents protect brain tissue against ischemic damage in rodents

5 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F1098-2396%28200104%2940%3A1%3C47%3A%3AAID-SYN1025%3E3.0.CO%3B2-S

Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1098-2396%28200104%2940%3A1%3C47%3A%3AAID-SYN1025%3E3.0.CO%3B2-S

Aging, energy, and oxidative stress in neurodegenerative diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1098-2396%28200104%2940%3A1%3C47%3A%3AAID-SYN1025%3E3.0.CO%3B2-S

In vivo effects of the kavapyrones (+)-dihydromethysticin and (+/-)-kavain on dopamine, 3,4-dihydroxyphenylacetic acid, serotonin and 5-hydroxyindoleacetic acid levels in striatal and cortical brain regions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1098-2396%28200104%2940%3A1%3C47%3A%3AAID-SYN1025%3E3.0.CO%3B2-S

Oxidative stress, glutamate, and neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1098-2396%28200104%2940%3A1%3C47%3A%3AAID-SYN1025%3E3.0.CO%3B2-S

Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1098-2396%28200104%2940%3A1%3C47%3A%3AAID-SYN1025%3E3.0.CO%3B2-S

In vivo microdialysis study of (+/-)-kavain on veratridine-induced glutamate release.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1098-2396%28200104%2940%3A1%3C47%3A%3AAID-SYN1025%3E3.0.CO%3B2-S

Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1098-2396%28200104%2940%3A1%3C47%3A%3AAID-SYN1025%3E3.0.CO%3B2-S

(+/-)-Kavain inhibits veratridine-activated voltage-dependent Na(+)-channels in synaptosomes prepared from rat cerebral cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1098-2396%28200104%2940%3A1%3C47%3A%3AAID-SYN1025%3E3.0.CO%3B2-S

(+/-)-kavain inhibits the veratridine- and KCl-induced increase in intracellular Ca2+ and glutamate-release of rat cerebrocortical synaptosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1098-2396%28200104%2940%3A1%3C47%3A%3AAID-SYN1025%3E3.0.CO%3B2-S

Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in the mouse: relationships between monoamine oxidase, MPTP metabolism and neurotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1098-2396%28200104%2940%3A1%3C47%3A%3AAID-SYN1025%3E3.0.CO%3B2-S

The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1098-2396%28200104%2940%3A1%3C47%3A%3AAID-SYN1025%3E3.0.CO%3B2-S

Do NMDA receptor antagonists protect against MPTP-toxicity? Biochemical and immunocytochemical analyses in black mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1098-2396%28200104%2940%3A1%3C47%3A%3AAID-SYN1025%3E3.0.CO%3B2-S

1-Methyl-4-phenylpyridinium ion (MPP+): Identification of a metabolite of MPTP, a toxin selective to the substantia nigra

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1098-2396%28200104%2940%3A1%3C47%3A%3AAID-SYN1025%3E3.0.CO%3B2-S

Thalamic, subthalamic nucleus and internal pallidum stimulation in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1098-2396%28200104%2940%3A1%3C47%3A%3AAID-SYN1025%3E3.0.CO%3B2-S

Etiology and pathogenesis of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1098-2396%28200104%2940%3A1%3C47%3A%3AAID-SYN1025%3E3.0.CO%3B2-S

In vivo protection of striatum from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1098-2396%28200104%2940%3A1%3C47%3A%3AAID-SYN1025%3E3.0.CO%3B2-S

Parkinson's disease: a major hypokinetic basal ganglia disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1098-2396%28200104%2940%3A1%3C47%3A%3AAID-SYN1025%3E3.0.CO%3B2-S

MK-801 fails to protect against the dopaminergic neuropathology produced by systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice or intranigral 1-methyl-4-phenylpyridinium in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1098-2396%28200104%2940%3A1%3C47%3A%3AAID-SYN1025%3E3.0.CO%3B2-S

Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1098-2396%28200104%2940%3A1%3C47%3A%3AAID-SYN1025%3E3.0.CO%3B2-S

Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1098-2396%28200104%2940%3A1%3C47%3A%3AAID-SYN1025%3E3.0.CO%3B2-S

Inhibition of platelet MAO-B by kava pyrone-enriched extract from Piper methysticum Forster (kava-kava)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1098-2396%28200104%2940%3A1%3C47%3A%3AAID-SYN1025%3E3.0.CO%3B2-S

Systemic administration of NMDA and AMPA receptor antagonists reverses the neurochemical changes induced by nigrostriatal denervation in basal ganglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1098-2396%28200104%2940%3A1%3C47%3A%3AAID-SYN1025%3E3.0.CO%3B2-S

Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1098-2396%28200104%2940%3A1%3C47%3A%3AAID-SYN1025%3E3.0.CO%3B2-S

Effects of cytisine on hydroxyl radicals in vitro and MPTP-induced dopamine depletion in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1098-2396%28200104%2940%3A1%3C47%3A%3AAID-SYN1025%3E3.0.CO%3B2-S

Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1098-2396%28200104%2940%3A1%3C47%3A%3AAID-SYN1025%3E3.0.CO%3B2-S

Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1098-2396%28200104%2940%3A1%3C47%3A%3AAID-SYN1025%3E3.0.CO%3B2-S

[Kawa pyrone--a new kind of substance group of central muscle relaxants of the mephenesin type]

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1098-2396%28200104%2940%3A1%3C47%3A%3AAID-SYN1025%3E3.0.CO%3B2-S

Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1098-2396%28200104%2940%3A1%3C47%3A%3AAID-SYN1025%3E3.0.CO%3B2-S

Cerebroprotective effect of lamotrigine after focal ischemia in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1098-2396%28200104%2940%3A1%3C47%3A%3AAID-SYN1025%3E3.0.CO%3B2-S

10.1002/1098-2396(200104)40:1<47::AID-SYN1025>3.0.CO;2-S

21 January 2018

Identifiers

DOI

1 reference

5 July 2017

1 reference